Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

  • Technology appraisal guidance
  • TA375
  • Published: 

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report addendum

Assessment report addendum which details changes to the Assessment Report between August 2013 and February 2015

This page was last updated: 18 March 2015